DelveInsight’s “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the IgA Nephropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging IgA Nephropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current IgA Nephropathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
IgA Nephropathy: An Overview
IgA Nephropathy (IgAN) is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. IgAN occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys.
IgAN is the most common glomerular disease worldwide but varies largely geographically. Studies assess the prevalence of IgAN in different regions and analyze factors responsible for geographic differences. According to one such prominent study, IgAN is more frequent in Asian populations (45 cases per million population in Japan) than in Caucasians (31 cases per million population/y in France).
Conventional major treatments to manage IgAN include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. Other treatments include corticosteroids to slow the progression of the disease and other immunosuppressants like mycophenolate mofetil (MMF), cyclophosphamide, etc. There are no approved therapies for IgA Nephropathy in Japan and China, with current treatment being done primarily by ACE inhibitors/ARBs, immunosuppressants, and corticosteroids.
IgA Nephropathy Market Key Facts
-
Among EU4 countries, Germany accounted for the maximum market size in 2022, while Spain occupied the bottom of the ladder.
-
The total number of prevalent cases of IgA Nephropathy in the United States was around ~193,700 cases in 2022.
-
Among the EU4 countries, Germany accounted for the highest IgA Nephropathy prevalent cases, followed by France, whereas Spain accounted for the lowest number of prevalent cases in 2022.
-
EU4 and the UK accounted for ~165,000 prevalent cases of IgAN in 2022.
-
Japan accounted for about 88,000 diagnosed prevalent cases of IgA Nephropathy in 2022.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging IgA Nephropathy pipeline therapies. It also thoroughly assesses the IgA Nephropathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed IgA Nephropathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
IgA Nephropathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted IgA Nephropathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted IgA Nephropathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the IgA Nephropathy Epidemiology, Segmented as –
-
Total Prevalent Cases of IgA Nephropathy in the 7MM
-
Gender-specific Cases of IgA Nephropathy in the 7MM
-
Age-specific Cases of IgA Nephropathy in the 7MM
IgA Nephropathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the IgA Nephropathy market or expected to be launched during the study period. The analysis covers the IgA Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the IgA Nephropathy drugs based on their sale and market share.
The report also covers the IgA Nephropathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key IgA Nephropathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the IgA Nephropathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/iga-nephropathy-market
IgA Nephropathy Therapeutics Analysis
Conventional major treatments to manage IgAN include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. Other treatments include corticosteroids to slow the progression of the disease and other immunosuppressants like mycophenolate mofetil (MMF), cyclophosphamide, etc.
TARPEYO (budesonide) delayed-release capsule is the first FDA-approved drug for treating IgAN. It is indicated for IgAN patients at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. It was approved by the US FDA in December 2021 under an accelerated approval pathway, recognizing the urgent need for safe and efficacious therapies. Recently, Travere Therapeutics, Inc./Vifor Pharma’s FILSPARI (sparsentan) grabbed accelerated approval for IgAN treatment, availing another option for the IgAN population.
Although TARPEYO was approved and launched for IgAN, it is only a reformulated corticosteroid; hence there is a huge unmet need for targeted therapy for patients with extensive disease. To meet the need for disease-specific targeted treatments with a novel MoA, there are a few promising therapies in development, including narsoplimab (Omeros Corporation), atrasentan (Chinook Therapeutics), Iptacopan (Novartis Pharmaceuticals), sibeprenlimab (Otsuka Pharmaceutical), telitacicept (RemeGen), atacicept (Vera Therapeutics), and BION-1301 (Chinook Therapeutics). Currently, Travere Therapeutics is leading the therapeutics market with its IgA Nephropathy drug candidates in the most advanced stage of clinical development.
The IgAN treatment space is estimated to experience significant changes during the forecast period, owing to the launch of upcoming novel therapies and a robust pipeline of drugs developing to manage IgAN. However, the challenges of pricing, reimbursement, and associated side effects are two major factors likely to influence the market success of the upcoming therapies.
IgA Nephropathy Companies Actively Working in the Therapeutics Market Include
-
Omeros Corporation
-
Novartis Pharmaceuticals
-
Chinook Therapeutics
-
Visterra (a subsidiary of Otsuka Pharmaceutical)
-
Alnylam Pharmaceuticals
-
Vera Therapeutics
-
RemeGen
And Many Others
Emerging and Marketed IgA Nephropathy Therapies Covered in the Report Include:
-
Atrasentan: Chinook Therapeutics
-
Sparsentan: Travere Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/iga-nephropathy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. IgA Nephropathy Competitive Intelligence Analysis
4. IgA Nephropathy Market Overview at a Glance
5. IgA Nephropathy Disease Background and Overview
6. IgA Nephropathy Patient Journey
7. IgA Nephropathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. IgA Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. IgA Nephropathy Unmet Needs
10. Key Endpoints of IgA Nephropathy Treatment
11. IgA Nephropathy Marketed Therapies
12. IgA Nephropathy Emerging Drugs and Latest Therapeutic Advances
13. IgA Nephropathy Seven Major Market Analysis
14. Attribute Analysis
15. IgA Nephropathy Market Outlook (In US, EU5, and Japan)
16. IgA Nephropathy Companies Active in the Market
17. IgA Nephropathy Access and Reimbursement Overview
18. KOL Views on the IgA Nephropathy Market
19. IgA Nephropathy Market Drivers
20. IgA Nephropathy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/iga-nephropathy-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Parkinson’s Disease-Related Dementia Market
“Parkinson’s Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Parkinson’s Disease-Related Dementia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Parkinson’s Disease-Related Dementia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research